Board summary
Key figures
44,008
Registered population
56.7% aged 18–64
24.4%
Aged 65+
ICB 18.8% · England 17.9%
8.5%
Ethnic minority (non-White)
3.7% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 0.8% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
7,134
Hypertension register
+5.52% in 3 yrs · England +5.60%
412
SMI register
45.3% of Mole Valley's
625
COPD register
Reviews -6.08% in 3 yrs
Forecast to 2030
8,184
Hypertension patients, 2030
+1,050 on today
66.5%
QRISK ≥20% on statins, 2030
+2.01pp over 3 yrs
7.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews declined over three years.
Asthma review coverage fell 7.4% from 2023 to 2025 (England +4.4%) to 65.1% (England 65.7%), leaving about 920 patients unreviewed.
Age-five MMR booster lags first dose.
Age-five MMR coverage drops from 93.5% at dose 1 to 84.8% at dose 2, with 4-in-1 booster uptake at 79.3% against the 95.0% target.
SMI physical health checks exceed benchmarks.
Holding 45.3% of Mole Valley's severe mental illness register, the PCN achieves 86.3% blood pressure (England 83.4%) and 86.0% BMI checks (England 82.1%).
Population, age and ethnicity
Patients aged 65+ form 24.4% of the list, exceeding England's 17.9%
Patients aged 65+ represent 24.4% (10,750) of the 44,008 registered list, above Mole Valley (23.4%), NHS Surrey Heartlands Integrated Care Board (18.8%) and England (17.9%). Working-age patients (18-64) form 56.7% (24,961) and children (0-17) form 18.9% (8,297). Census usual residents show a 91.5% White population (Mole Valley 92.7%, ICB 85.3%, England 81.1%) and an 8.5% ethnic minority share, including 3.7% Asian / Asian British (Mole Valley 3.0%, ICB 7.7%, England 9.6%). Census figures reflect local residents rather than registered patients. This older demographic is consistent with substantial demand for chronic disease and frailty management.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Mole Valley local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Mole Valley LA) | 1,845 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 89.4% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.4% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Mole Valley LA) | 869 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Mole Valley LA) | 9.8 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 8.4 with 0.0% of patients in Core20 areas
Leatherhead PCN records an average IMD decile of 8.4, compared with 8.2 in Mole Valley, 7.9 in NHS Surrey Heartlands ICB, and 5.5 in England. Currently, 0.0% of registered patients live in Core20 areas, matching Mole Valley (0.0%) and below NHS Surrey Heartlands ICB (0.8%) and England (21.0%). Across all four practices, Core20 share is 0.0%, while average IMD deciles range from 7.9 at Molebridge Practice to 8.9 at Eastwick Park Med.pract. Zero area-level Core20 concentration means inclusion efforts could focus on clinical vulnerability rather than geographic targeting.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
412
SMI register
0.92% recorded prevalence
275
Learning disability register
0.62% recorded prevalence
18
Care homes, 566 beds
In the PCN catchment
8.3%
Provide unpaid care
Mole Valley, Census 2021
The PCN records 412 severe mental illness patients (45.3% of the borough total) and 275 learning disability patients (56.9% of the borough). Learning disability QOF prevalence fell 10.5% between 2023 and 2025 (England +5.4%). The PCN catchment includes 18 care homes with 566 beds. Trailing national prevalence change could reflect register maintenance or diagnostic recording differences, which local audit could test.
Severe mental illness: physical health checks
Recorded SMI prevalence is 0.9% (England 1.0%). Annual blood pressure (86.3%) and BMI checks (86.0%) exceed England (83.4% and 82.1%). Smoking cessation support fell 5.5 pp between 2023 and 2025 (England +0.1 pp) to 91.1% (England 94.2%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,134
Hypertension register
+5.52%
Register growth, 3 yrs
Mole Valley +3.55% · England +5.60%
−1.56pp
BP control, under 80
≤140/90 · −0.47pp aged 80+
+1,050
More patients by 2030
Forecast 8,184 (17.81%)
Hypertension case-finding and control
The PCN records 7,134 patients on its hypertension register, representing a prevalence of 16.0% (Mole Valley 16.3%, NHS Surrey Heartlands ICB 14.3%, England 15.2%). While 89.8% had a recent blood pressure reading (Mole Valley 90.8%, England 90.0%), blood pressure control in patients under 80 years is 65.3% (Mole Valley 69.3%, England 67.8%), having declined 2.3% between 2023 and 2025 (England +3.2%). In patients aged 80 and over, control is 79.6% (Mole Valley 81.1%, England 81.2%), down 0.6% (England +2.2%). Denominators include personalised care adjustments; observation periods were not supplied. Blood pressure control under 80 years is below borough and England benchmarks despite high measurement reach, which could reflect titration or review intervals, unverified locally.
Lipids and statins
Statin treatment reaches 69.9% in diabetes without cardiovascular disease (England 73.2%) and 80.8% in diabetes with cardiovascular disease (England 84.4%), while 62.3% with QRISK ≥ 20% receive lipid-lowering therapy (England 63.6%). Denominators include personalised care adjustments. Statin coverage trails England benchmarks across diabetic and high-risk cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 56,249 | £2.40 | £2.24 | £1.86 | £134,998 |
| Cardiovascular (all), 2025 | 76,153 | £4.96 | £4.74 | £3.33 | £377,719 |
In 2026, the PCN prescribed 56,249 items for lipid-regulating drugs at £2.40 per item, compared with £2.18 in Mole Valley, £2.24 in NHS Surrey Heartlands ICB, and £1.86 in England, spending £30,374 more than at England's unit cost. Higher unit cost than comparators could reflect local formulary choices, unverified locally.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−7.42%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+6.12%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 6.2% (2,624 patients) after 6.1% three-year growth between 2023 and 2025 (England +0.5%), but reviews fell 7.4% (England +4.4%) to 65.1% (Mole Valley 66.5%, England 65.7%), leaving about 920 unreviewed. COPD prevalence is 1.4% (625 patients; Mole Valley 1.5%, England 1.9%) following 10.3% growth (England +2.6%), while reviews fell 6.1% (England +2.8%) to 76.0% (Mole Valley 75.9%, England 76.4%). Slipping review rates could reflect capacity pressures, unverified locally.
Cancer register and children's immunisation
In Q1 2025/26, 12-month 6-in-1 coverage reached 89.2% against the 95.0% target. At age 5, MMR dose 1 is 93.5%, but MMR dose 2 is 84.8% (an 8.7 pp gap) and the 4-in-1 booster is 79.3% (NHS Surrey Heartlands ICB 85.0%). Cancer prevalence is 6.2% (2,763 patients; Mole Valley 5.5%, England 3.8%). Lower booster uptake could reflect recall timing differences, unverified locally.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
In 2022, NHS Surrey Heartlands ICB recorded 61.4% of staged cancers diagnosed at stage 1 or 2 (2,955 of 4,810 cases), exceeding England (55.3%) but 13.6 pp below the 75.0% national ambition by 2028. This represents an ICB shortfall of about 650 early-stage cases a year. Early-stage share rose 6 pp from 55.5% in 2013 to 61.4% in 2022, while known-stage completeness was 67.7% (4,810 of 7,106 cancers). These ICB figures reflect wider system performance. PCN cancer prevalence reached 6.2% (2,763 patients). Cervical screening fell 2.0% between 2023 and 2025 (England -1.0%) to 72.1%, with Ashlea Medical Practice at 68.9% and Molebridge Practice at 69.7%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Epsom and St Helier University Hospitals NHS Trust achieved 86.8% for 62-day cancer referral to treatment (England 71.2%, NHS Surrey and Sussex Integrated Care Board 71.5%, Surrey and Sussex Healthcare NHS Trust 70.0%, Kingston and Richmond NHS Foundation Trust 75.3%), 89.7% for 28-day faster diagnosis, and 99.2% for 31-day treatment. For diagnostic waits of 6+ weeks, Epsom and St Helier recorded 0.3% for MRI (Surrey and Sussex Healthcare NHS Trust 27.5%, England 21.4%) and 33.0% for colonoscopy (Surrey and Sussex Healthcare NHS Trust 15.1%, England 30.8%). Provider figures describe wider system performance rather than PCN delivery.
| Pathways within standard (%) | Epsom and St Helier | Kingston and Richmond | Surrey and Sussex Healthcare | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 89.70 | 80.07 | 77.74 | 79.29 | 79.32 |
| 31-day treatment (96%) | 99.16 | 98.77 | 96.20 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 86.82 | 75.32 | 69.97 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Epsom and St Helier | Kingston and Richmond | Surrey and Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 0.31 | 0.19 | 27.53 | 21.40 |
| CT | 1.06 | 0.00 | 18.49 | 9.92 |
| Echocardiography | 25.49 | 4.89 | 43.78 | 28.48 |
| Colonoscopy | 33.01 | 70.17 | 15.11 | 30.83 |
| Gastroscopy | 30.90 | 79.18 | 21.06 | 29.02 |
| All 15 DM01 tests | 6.83 | 31.56 | 28.50 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In June 2026, provisional Community Services Dataset records show that adults aged 65+ accounted for 69.6% of community contacts among Mole Valley borough residents (76,215 of 109,530 contacts). These borough figures describe wider system activity rather than PCN delivery, consistent with the PCN having 24.4% of registered patients aged 65+.
Practice variation and patient experience
Phone access spans 9.8 pp and vaccination achievement spans 62.1 pp across practices
In 2025/26, overall QOF achievement ranged from 87.6% at Molebridge Practice to 95.3% at Eastwick Park Med.pract. (England 92.5%). Vaccination and immunisation achievement spanned 62.1 pp, from 15.6% at Molebridge Practice to 77.7% at Fairfield Medical Centre (England 55.2%), while clinical scores ranged from 96.1% at Fairfield Medical Centre to 100.0% at Eastwick Park Med.pract. (England 97.1%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Eastwick Park | 111 | 0.0 | 71.9% | 68.9% | 85.9% |
| Fairfield | 126 | 0.0 | 70.1% | 79.0% | 82.1% |
| Ashlea Medical | 110 | 0.0 | 62.3% | 81.6% | 78.8% |
| Molebridge | 108 | 0.0 | 62.0% | 68.4% | 77.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nineteen of 25 tracked measures trailed England's three-year change, led by routine reviews
Between 2023 and 2025, 19 of 25 tracked measures trailed England's change. The widest lags were in reviews: heart failure fell 3.5% (England +8.7%), asthma fell 7.4% (England +4.4%), COPD fell 6.1% (England +2.8%), and smoking cessation offers dropped 5.5 pp (England +0.1 pp). In contrast, SMI psychosis alcohol recording rose 7.2 pp to 87.4% (England 81.8%), SMI blood pressure checks reached 86.3% (England 83.4%), and diabetes HbA1c control without frailty reached 61.4% (England 57.4%). Slipping review rates could reflect capacity pressures, which local recall audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Heart failure reviews
Asthma reviews
COPD reviews
Smoking support (SMI)
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Mole Valley | Asset | PCN | Mole Valley |
|---|---|---|---|---|---|
| Care homes (catchment) | 18 (566 beds) | n/a | Schools (catchment) | 47 | n/a |
| Children's centres | 3 | 6 | Places of worship | 34 | 65 |
| Libraries | 2 | 3 | Food banks (VCS) | 2 | 3 |
| Homelessness support (VCS) | 1 | 1 | Day centres (VCS) | n/a | 2 |
| Children and young people (VCS) | 1 | 1 | Carers support groups (VCS) | 1 | 2 |
| Primary schools (LA maintained) | 7 | 10 | Primary academies | 5 | 11 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Age-five booster recall and workflow review
In Q1 2025/26, age-5 MMR dose 2 is 84.8% (8.7 pp below dose 1 at 93.5%; ICB 87.0%) and 4-in-1 booster coverage is 79.3% against the 95.0% target. For discussion: audit age-five recall lists for children with one MMR dose and offer flexible booster clinic slots. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Structured asthma annual review recall
Asthma annual review coverage is 65.1% (Mole Valley 66.5%, England 65.7%) after a 7.4% fall from 2023 to 2025 (England +4.4%), leaving about 920 of 2,624 patients unreviewed. For discussion: run a single recall template paired with inhaler prescribing checks and remote or after-school review slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Under-80 hypertension and lipid titration review
Across 7,134 hypertension patients, under-80 BP control is 65.3% (England 67.8%) after a 2.3% fall (England +3.2%), and QRISK >= 20% lipid therapy is 62.3% (England 63.6%). For discussion: run pharmacist-led recall clinics for recorded patients above BP target or with QRISK >= 20% untreated. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Proactive frailty review coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Clinical register inclusion audit (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation offer audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Age-five booster recall and workflow review (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Structured asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Under-80 hypertension and lipid titration review (p12) | Hypertension register · Hypertension patients with a recent BP reading · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
